

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (Withdrawn) A therapeutic agent for glioblastoma, which comprises a compound having an activity of inhibiting an AMPA receptor as the active ingredient.
2. (Withdrawn) A therapeutic agent for glioblastoma according to claim 1, wherein the compound having an activity of inhibiting an AMPA receptor is [7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-1(2H)-yl]acetic acid or a salt thereof or a hydrate thereof.
3. (Withdrawn) A therapeutic agent for glioblastoma according to claim 1, wherein the compound having an activity of inhibiting an AMPA receptor is 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)-quinoxaline or a salt thereof.
4. (Withdrawn) A therapeutic agent for glioblastoma according to claim 1, wherein the compound having an activity of inhibiting an AMPA receptor is 2-[N-(4-chlorophenyl)-N-methylamino]-4H-pyrido[3,2-e]-1,3-thiazin-4-one or a salt thereof.
5. (Withdrawn) A pharmaceutical composition for use as a therapeutic agent for glioblastoma, the pharmaceutical composition containing a therapeutically effective amount of a

compound having an activity of inhibiting an AMPA receptor and a pharmaceutically acceptable carrier.

6. (Withdrawn) A pharmaceutical composition according to claim 5, wherein the compound having an activity of inhibiting an AMPA receptor is [7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-1(2H)-yl]acetic acid or a salt thereof or a hydrate thereof.

7. (Withdrawn) A pharmaceutical composition according to claim 5, wherein the compound having an activity of inhibiting an AMPA receptor is 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)-quinoxaline or a salt thereof.

8. (Withdrawn) A pharmaceutical composition according to claim 5, wherein the compound having an activity of inhibiting an AMPA receptor is 2-[N-(4-chlorophenyl)-N-methylamino]-4H-pyrido[3,2-e]-1,3-thiazin-4-one or a salt thereof.

9. (Withdrawn) Use of a compound having an activity of inhibiting an AMPA receptor for the manufacture of a medicament for treating glioblastoma comprising a clinically effective amount of the compound.

10. (Withdrawn) Use according to claim 9, wherein the compound having an activity of inhibiting an AMPA receptor is [7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-1(2H)-yl]acetic acid or a salt thereof or a hydrate thereof.

11. (Withdrawn) Use according to claim 9, wherein the compound having an activity of inhibiting an AMPA receptor is 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)-quinoxaline or a salt thereof.

12. (Withdrawn) Use according to claim 9, wherein the compound having an activity of inhibiting an AMPA receptor is 2-[N-(4-chlorophenyl)-N-methylamino]-4H-pyrido[3,2-e]-1,3-thiazin-4-one or a salt thereof or a hydrate thereof.

13. (currently amended): A method for treating glioblastoma comprising administering a therapeutically effective amount of a compound having an activity of inhibiting an α -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor to a patient with the disease.

14. (Original) A method according to claim 13, wherein the compound having an activity of inhibiting an AMPA receptor is [7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-1(2H)-yl]acetic acid or a salt thereof or a hydrate thereof.

15. (Original) A method according to claim 13, wherein the compound having an activity of inhibiting an AMPA receptor is 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)-quinoxaline or a salt thereof.

16. (Original) A method according to claim 13, wherein the compound having an activity of inhibiting an AMPA receptor is 2-[N-(4-chlorophenyl)-N-methylamino]-4H-pyrido[3,2-e]-1,3-thiazin-4-one or a salt thereof.

17. (New) A method according to claim 13, wherein the compound having an activity of inhibiting an AMPA receptor is 1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine or a salt thereof.

18. (New) A method according to claim 13, wherein the compound having an activity of inhibiting an AMPA receptor is 7-acetyl-5-(4-aminophenyl)-8(R)-methyl-8,9-dihydro-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine or a salt thereof.